How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market [The Motley Fool]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: The Motley Fool
Kody Kester(tmfkodyk)Key PointsThe FDA breakthrough therapy designation for AbbVie and Roche's Venclexta and azacitidine comes following impressive results in the phase b study.Large-cap biopharmaceuticalsNYSE:ABBVOTC:RHHBYApproximately 0,000 patients in the U.S. are diagnosed with MDS each year. Unfortunately, 0% of patients with this diagnosis go on to develop acute myeloid leukemia, or AML. The condition is diagnosed when "0 out of every 00 white blood cells in the bone marrow is a blast cell," according to the Aplastic Anemia and MDS International Foundation or AAMDS, resulting in an inability to normally produce blood.Image source: Getty Images.The blast cells ("very young or immature white blood cells," per AAMDS) then go on to rapidly make copies of themselves, which inhibits the body's capability to produce red blood cells and platelets. This leads to just a 6% five-year survival rate in patients over the age of 0 with AML.Physicians are able to differentiate between lower-ris
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Health Canada authorizes Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types [Yahoo! Finance]Yahoo! Finance
- Health Canada authorizes Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer typesPR Web
- FDA Roundup: April 19, 2024 [Yahoo! Finance]Yahoo! Finance
- Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion [Yahoo! Finance]Yahoo! Finance
- Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer [Yahoo! Finance]Yahoo! Finance